Abstract | BACKGROUND: METHODS: A total of 407 patients who received first diagnosis of recurrent breast cancer and treatment at National Kyushu Cancer Center between 1992 and 2008 were retrospectively evaluated. As AIs and trastuzumab were approved for clinical use in Japan in 2001, the patients were divided into two time cohorts depending on whether the cancer recurred before or after 2001. Cohort A: 170 patients who were diagnosed between 1992 and 2000. Cohort B: 237 patients who were diagnosed between 2001 and 2008. Tumor characteristics, treatments, and outcome were compared. RESULTS: Fourteen percent of cohort A and 76% of cohort B received AIs and/or trastuzumab (P < 0.001). The median overall survival (OS) times after breast cancer recurrence were 1.7 years and 4.2 years for these respective cohorts (P < 0.001). Both the time period and treatment of AIs and/or trastuzumab for recurrent disease were significant prognostic factors in multivariate analysis (cohort B vs. cohort A: HR = 0.70, P = 0.01; AIs and/or trastuzumab for recurrent disease: yes vs. no: HR = 0.46, P < 0.001). When patients were categorized into 4 subgroups by the expression of hormone receptor (HR) and HER-2 status, the median OS times of the HR-positive/HER-2-negative, HR-positive/HER-2-positive, HR-negative/HER-2-positive, and HR-negative/HER-2-negative subtypes were 2.2, 2.4, 1.6, and 1.0 years in cohort A and 4.5, 5.1, 5.0, and 1.4 years in cohort B. CONCLUSIONS: The prognosis of patients with recurrent breast cancer was improved over time following the introduction of AIs and trastuzumab and the survival improvement was apparent in HR- and/or HER-2-positive tumors.
|
Authors | Hideo Shigematsu, Hidetoshi Kawaguchi, Yoshiaki Nakamura, Kimihiro Tanaka, Satoko Shiotani, Chinami Koga, Sumiko Nishimura, Kenichi Taguchi, Kenichi Nishiyama, Shinji Ohno |
Journal | BMC cancer
(BMC Cancer)
Vol. 11
Pg. 118
(Mar 31 2011)
ISSN: 1471-2407 [Electronic] England |
PMID | 21453503
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Aromatase Inhibitors
- ERBB2 protein, human
- Receptor, ErbB-2
- Trastuzumab
|
Topics |
- Aged
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Aromatase Inhibitors
(administration & dosage, adverse effects)
- Breast Neoplasms
(drug therapy, mortality, pathology, physiopathology)
- Carcinoma
(drug therapy, mortality, pathology, physiopathology)
- Female
- Humans
- Middle Aged
- Prognosis
- Receptor, ErbB-2
(metabolism)
- Recurrence
- Retrospective Studies
- Survival Analysis
- Trastuzumab
|